Gilead Sciences’ (GILD) Hold Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...
The American Journal of Managed Care5h
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
Gilead Sciences Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Regenerative Medicine Market Projected To Witness Substantial Growth, 2025-2032 Novartis AG (Switzerland), Biogen
Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...